Ovarian Cancer | Specialty

MEK Inhibitor Misses Mark in Phase III Ovarian Cancer Study

April 1st 2016

The MEK inhibitor binimetinib failed to improve progression-free survival compared with physician's choice of chemotherapy for patients with low-grade serous ovarian cancer.

Trial of Ovarian Chemotherapy Regimens Fails to Provide Clarity

March 22nd 2016

Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.

Phase III Studies Aim to Expand Olaparib's Ovarian Cancer Approval

March 22nd 2016

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.

Trial Tests Combo of Pexidartinib and Pembrolizumab in Ovarian and Other Solid Tumors

March 21st 2016

An ongoing clinical trial has begun the process of evaluating whether the addition of a booster agent can take the anticancer activity of PD-1 directed immunotherapy to another level.

Researchers Seek to Optimize PARP Inhibitors in Ovarian Cancer

March 21st 2016

Shannon Westin, MD, discusses refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities.

Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer

March 20th 2016

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

BRCA Mutations Linked to Longer Survival in Ovarian Cancer

March 19th 2016

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival outcomes versus patients without HR mutations.

Dr. Gershenson on Evolution of Targeted Therapies for Rare Gynecologic Malignancies

February 11th 2016

David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.

Multimodal Ovarian Cancer Screening Method Shows Promise in Large Trial

December 19th 2015

Multimodal screening using CA-125 and a risk assessment algorithm could reduce the risk of mortality from ovarian cancer in certain women.

New Concepts Emerging in Treatment of Advanced Ovarian Cancer

December 16th 2015

Although ovarian cancer remains a formidable challenge in the United States, therapeutic advances achieved during the past several years have provided specialists in gynecologic malignancies with more options than ever for treating patients.

Adjuvant Hormonal Therapy Linked to Improved Outcomes in Ovarian Cancer

December 16th 2015

Adjuvant hormone therapy was associated with a 37% reduction in the risk of death in women with epithelial ovarian cancer.

Dr. Sanaz Memarzadeh on Chemotherapy Resistant Tumor Cells in Ovarian Cancer

December 16th 2015

Sanaz Memarzadeh, MD, PhD, associate professor of Obstetrics and Gynecology, and the director of the Gynecologic Oncology Discovery Lab at UCLA, discusses her preclinical research on resistant tumor cells in ovarian cancer.

Multi-Epitope Vaccine Granted Orphan Designation for Ovarian Cancer

December 14th 2015

The FDA has granted an orphan drug designation to the multi-epitope folate receptor alpha (FRα) vaccine TPIV 200 as a treatment for patients with ovarian cancer.

FDA Approves New Melanoma Combo, ASH Abstracts Released, Early Ovarian Cancer Data, and More

November 13th 2015

Is Neoadjuvant Chemo Justified in Ovarian Cancer?

November 5th 2015

The use of neoadjuvant chemotherapy in advanced ovarian cancer continues to increase, even though the practice has not been shown to improve survival versus primary cytoreduction.

Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers

November 5th 2015

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

Immunotherapy Not Ready for Prime Time in Ovarian Cancer

November 5th 2015

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

BRCA+ Patients May Have Higher Risk of Serous Uterine Cancers After RRSO

October 15th 2015

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer

October 15th 2015

The evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.

Dr. Memarzadeh on Recurrence Rates in Ovarian Cancer

October 13th 2015

Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.